Dr Amir Zalcenstein
Amir Zalcenstein has relocated to Melbourne from Israel in 2014. Prior to joining OneVentures and while in Israel, Amir was Head of Business Development for BiondVax, a publicly traded company developing a Universal Flu Vaccine. Prior, Amir served as CEO of Amorphical (developing the next generation of Calcium-based therapies) and SoluBest, a drug delivery company advancing a proprietary technology for oral delivery of insoluble drugs.
Amir holds a PhD in Molecular Biology from the Weizmann Institute of Science and an Executive MBA from Technion, Israel.
Amir brings a strong Israeli venture perspective to the team and extensive international operational experience.